European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.2.6. Chronic graft dysfunction. Late recurrence of other diseases.
A. In the rare case of recurrent lupus nephritis, no particular treatment is recommended. Only in the few patients with clinically evident flare up is a reinforcement of immunosuppression recommended. B. Recurrence of Henoch-Schönlein purpura may occur even in the absence of clinical signs and symptoms. The prognosis for the graft may be severe, particularly in adults. C. In the case of recurrent ANCA-associated renal or systemic vasculitis, it is recommended to reinforce the immunosuppression with appropriate agents. D. Since diabetic nephropathy recurs almost invariably after transplantation, strict control of diabetes and hypertension, and the use of ACE inhibitors and/or angiotensin II receptor antagonists are recommended in order to prevent or slow the risk of recurrence.
D019268:Antibodies, Antineutrophil Cytoplasmic / Q000032:analysis; D002908:Chronic Disease; D003928:Diabetic Nephropathies / Q000628:therapy; D006801:Humans; D011695:IgA Vasculitis / Q000628:therapy; D007674:Kidney Diseases / Q000628:therapy*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008181:Lupus Nephritis / Q000628:therapy; D012008:Recurrence; D014657:Vasculitis / Q000628:therapy
D019268:Antibodies, Antineutrophil Cytoplasmic